Analysts Offer Predictions for Prime Medicine Q1 Earnings

Prime Medicine, Inc. (NYSE:PRME) – Stock analysts at Wedbush issued their Q1 2026 earnings per share (EPS) estimates for shares of Prime Medicine in a note issued to investors on Thursday, May 8th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings per share of ($0.38) for the quarter. Wedbush has a “Outperform” rating and a $13.00 price objective on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. Wedbush also issued estimates for Prime Medicine’s Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.36) EPS and Q4 2026 earnings at ($0.35) EPS.

Prime Medicine (NYSE:PRME) last released its earnings results on Friday, March 7th. The company reported ($1.65) EPS for the quarter. During the same period in the prior year, the company earned ($2.18) earnings per share.

A number of other brokerages have also recently weighed in on PRME. Chardan Capital increased their price target on Prime Medicine from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Prime Medicine in a research report on Wednesday, March 19th. Finally, StockNews.com upgraded Prime Medicine to a “sell” rating in a research report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.14.

Prime Medicine Stock Down 1.5%

NYSE:PRME opened at $1.30 on Monday. The business’s 50 day moving average is $1.66 and its two-hundred day moving average is $2.61. The company has a market cap of $170.51 million, a PE ratio of -0.63 and a beta of 1.90. Prime Medicine has a 52 week low of $1.12 and a 52 week high of $8.27.

Institutional Trading of Prime Medicine

Several hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC raised its stake in Prime Medicine by 24.6% during the 4th quarter. ProShare Advisors LLC now owns 22,186 shares of the company’s stock valued at $65,000 after acquiring an additional 4,375 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Prime Medicine by 20.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 27,811 shares of the company’s stock valued at $81,000 after acquiring an additional 4,725 shares in the last quarter. Levin Capital Strategies L.P. raised its stake in Prime Medicine by 7.1% during the 4th quarter. Levin Capital Strategies L.P. now owns 75,000 shares of the company’s stock valued at $219,000 after acquiring an additional 5,000 shares in the last quarter. Rhumbline Advisers raised its stake in Prime Medicine by 13.8% during the 1st quarter. Rhumbline Advisers now owns 81,900 shares of the company’s stock valued at $163,000 after acquiring an additional 9,944 shares in the last quarter. Finally, American Century Companies Inc. bought a new stake in Prime Medicine during the 4th quarter valued at $33,000. Institutional investors own 70.37% of the company’s stock.

Prime Medicine Company Profile

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.